Stinging Nettle Root for Prostate and BPH

If you are getting up three times a night, standing at the toilet waiting for something to happen, and finishing with the distinct sense that your bladder is not actually empty — you are describing the problem nettle root has been studied for. This is nettle’s best indication, the one place where there is a genuine placebo-controlled trial literature rather than a pile of laboratory experiments and folklore.

It is also the place where the root-versus-leaf distinction stops being academic. Nettle leaf does nothing for the prostate. Not less, not weakly — nothing. It contains none of the sterols and lignans the prostate research is about. If your bottle does not say radix or “root”, you are taking the wrong part of the plant for this purpose.

What BPH Is, in Plain Language
Why the Root and Only the Root
How Nettle Root Might Work
The One Big Trial
The Combination Products — and Their Blind Spot
PSA, Finasteride, and the Thing That Actually Matters
Does It Shrink the Prostate?
Dose, Form, Cost and How Long to Give It
Where Nettle Root Sits Next to Real Drugs
Get the Diagnosis First — This Part Is Not Optional
Cautions and Interactions
Key Research Papers
Connections

What BPH Is, in Plain Language

The prostate is a walnut-sized gland that sits directly below the bladder, and the urethra — the tube urine leaves through — runs straight through the middle of it. That anatomy is the whole problem. From roughly the age of forty onwards, the gland tends to enlarge. By the seventies, most men have some degree of it. As it grows, it squeezes the tube passing through it, and the bladder has to work harder to push urine past the obstruction.

The resulting cluster is called lower urinary tract symptoms (LUTS), and it splits into two kinds:

Voiding symptoms — a weak or splitting stream, hesitancy (standing there waiting), straining, dribbling at the end, and the sense of incomplete emptying. These come from the physical obstruction.
Storage symptoms — urgency, frequency, and nocturia (waking at night to urinate). These come from a bladder wall that has thickened and become irritable from years of pushing against resistance. Nocturia is usually the symptom that finally sends men to the doctor, because it is the one that wrecks sleep.

Clinicians score all this with the International Prostate Symptom Score (IPSS) — seven questions, each 0 to 5, so 0 to 35 total. Roughly: 0–7 mild, 8–19 moderate, 20–35 severe. A change of about 3 points is the smallest one a man typically notices; 4 to 6 points is a change he would call meaningful. Keep those numbers in mind, because every trial below reports IPSS and the raw figures mean nothing without a sense of scale.

Two things BPH is not: it is not cancer, and it is not a precursor to cancer. Benign prostatic hyperplasia and prostate cancer are separate diseases that happen to occur in the same organ in the same age group. Having one does not cause the other. Unfortunately, they can produce identical symptoms — which is the subject of a later section.

Why the Root and Only the Root

Nettle root (Urticae radix) and nettle leaf (Urticae folium) have almost nothing chemically in common. The European Medicines Agency publishes them as two separate herbal monographs. Chrubasik and colleagues, writing the definitive review in Phytomedicine in 2007, split it into two papers for the same reason — Part I for the aerial parts, Part II for the root.

The root’s relevant constituents are:

Phytosterols, principally beta-sitosterol and its glucoside. Beta-sitosterol has its own separate BPH literature, independent of nettle.
Lignans — secoisolariciresinol and 3,4-divanillyltetrahydrofuran, plus the metabolites gut bacteria make from them (enterodiol, enterolactone).
Polysaccharides with anti-inflammatory activity in cell assays.
Urtica dioica agglutinin (UDA), a small lectin that binds N-acetylglucosamine and is unusually heat- and acid-stable.
Scopoletin, a coumarin, used in some products as an analytical marker for standardisation.

None of these are present in the leaf in meaningful quantity. When you see a “nettle complex” capsule containing whole-plant powder, understand that whatever root is in there has been diluted by leaf material that contributes nothing to this indication.

How Nettle Root Might Work

Several mechanisms have been proposed. All of them come from test-tube and animal work, none of them has been demonstrated to be the reason men feel better, and it is entirely possible that the clinical effect comes from something not on this list.

Sex hormone-binding globulin

SHBG is the carrier protein that transports testosterone in the blood; the fraction bound to SHBG is not biologically available. Schöttner and colleagues showed in 1997 that lignans isolated from nettle root, and the metabolites gut bacteria produce from them, bind to human SHBG in a cell-free assay. The idea is that this changes how much free androgen reaches prostate tissue. This is a binding experiment in a tube. Whether it happens at the concentrations a capsule produces in a living man is unknown.

Aromatase and 5-alpha-reductase

Nettle root extracts weakly inhibit both enzymes in vitro — aromatase, which converts testosterone to estradiol, and 5-alpha-reductase, which converts testosterone to the more potent dihydrotestosterone (DHT) that drives prostate growth. The word doing the work in that sentence is weakly. Finasteride inhibits 5-alpha-reductase so effectively that it halves circulating PSA. Nettle root does not measurably change PSA in men, which tells you the enzyme inhibition is not happening to any comparable degree in the body.

Anti-proliferative and anti-inflammatory effects

Konrad and colleagues reported in 2000 that a nettle root extract slowed the growth of human prostate cancer cell lines in culture. That is a cell-culture observation about cancer cells, and it should not be read as evidence that nettle treats or prevents prostate cancer — a great many substances slow cell growth in a dish. Lichius and Muth showed in 1997 that nettle root extract reduced experimentally induced prostate enlargement in mice. Nahata and Dixit reported something similar in testosterone-induced prostatic hyperplasia in rats in 2012. Animal models of induced BPH are useful for generating hypotheses and famously unreliable for predicting human outcomes.

The honest summary of mechanism

There is no single agreed pathway. The most reasonable reading is that a combination of mild anti-inflammatory and mild hormone-modulating actions produces a modest reduction in the tissue swelling and irritability that generate symptoms — without doing anything dramatic to the underlying enlargement.

The One Big Trial

If you only read one paper about nettle root, read Safarinejad’s 2005 trial in the Journal of Herbal Pharmacotherapy. It is by a wide margin the largest and most informative human study of nettle root alone.

Design. 620 men, randomized, double-blind, placebo-controlled, partial crossover, six months. 558 men (90%) completed. At six months the blind was broken and the placebo group was switched onto nettle; both groups continued to 18 months.

Results at six months, by intention to treat:

Symptom improvement: 232 of 287 men (81%) on nettle reported improved LUTS, versus 43 of 271 (16%) on placebo (P < 0.001).
IPSS: fell from 19.8 to 11.8 with nettle; from 19.2 to 17.7 with placebo (P = 0.002). That is an 8-point drop against a 1.5-point drop — well past the 3-point threshold a man would notice, and moving the average patient from “moderate, verging on severe” into the middle of the moderate band.
Peak flow rate (Q_max): improved by 8.2 mL/s on nettle versus 3.4 mL/s on placebo (P < 0.05).
Post-void residual urine: fell from 73 mL to 36 mL on nettle, with no appreciable change on placebo.
PSA and testosterone: unchanged in both groups.
Prostate volume on transrectal ultrasound: a modest fall from 40.1 mL to 36.3 mL on nettle (P < 0.001); no change on placebo.
Side effects: none identified in either group.
At 18 months: only the men who stayed on treatment kept their gains.

What to make of it. Those are large, clean numbers — and that is exactly why they deserve scrutiny. An 81% versus 16% responder split and a five-point separation in flow rate are bigger than anything reported for the herbal combination products, and bigger than most single-agent phytotherapy trials in this field. The trial has not been replicated at that scale. The author’s own conclusion is unusually cautious: “Further clinical trials should be conducted to confirm these results before concluding that Urtica dioica is effective.” When the investigator who got the positive result says that, take it seriously.

The second single-herb trial, by Ghorbanibirgani and colleagues in 2013, randomized 100 men double-blind and also reported symptom improvement over placebo. It is a much shorter report with far less detail, published as a brief article, and it does not add much beyond a second positive result in a small sample.

The Combination Products — and Their Blind Spot

Most of the trial literature people cite for nettle root is not actually about nettle root. It is about fixed combinations, and this is the single biggest interpretive trap on this subject.

Nettle root plus saw palmetto (PRO 160/120)

A German product combining 160 mg of saw palmetto (Serenoa repens) fruit extract with 120 mg of nettle root extract, taken twice daily. It has been through several trials:

Lopatkin 2005 — placebo-controlled, double-blind, multicentre; the combination improved IPSS more than placebo over 24 weeks, and an open extension (Lopatkin 2007) followed men out considerably further with maintained benefit and good tolerability.
Sökeland 2000 — the widely quoted “as good as finasteride” paper. It is a subgroup analysis of 431 men from a 543-man randomized double-blind trial comparing PRO 160/120 with finasteride. Peak flow rose 1.9 mL/s on the herbal combination and 2.4 mL/s on finasteride — no statistically significant difference (P = 0.52) — and IPSS improved in both arms with no significant separation. More men in the finasteride arm reported adverse events. Two things are worth noticing: the paper was designed to ask whether baseline prostate volume predicts response, not to establish equivalence; and “no significant difference” in a trial of this size is not the same as “proven equivalent”.
Engelmann 2006 — a randomized double-blind comparison against tamsulosin, an alpha-blocker, which also found comparable symptom improvement.

Nettle root plus pygeum

Krzeski and colleagues (1993) studied 134 men on a combination of 300 mg nettle root extract with 25 mg Pygeum africanum bark extract. Flow, residual urine and nocturia all improved significantly over 28 and 56 days. But read the design carefully: this was a double-blind comparison of the standard dose against half the standard dose. There was no placebo group at all. The conclusion the authors drew — correctly — was that the half dose works as well as the full dose. It cannot tell you whether either dose beats placebo, and it certainly cannot tell you what the nettle contributed as opposed to the pygeum.

Why this matters

None of these trials can attribute their result to nettle. A two-herb product that beats placebo has demonstrated that the product works. It has said nothing about which ingredient did it, or whether one of them is inert. Saw palmetto has its own large independent literature — including the NIH-funded CAMUS trial (Barry 2011), which escalated saw palmetto up to three times the usual dose in 369 men and found no benefit over placebo on IPSS at any dose. That result complicates the combination story considerably: if the saw palmetto component may be doing nothing, the combination trials become indirect evidence for nettle, and if the nettle component may be doing nothing, they become evidence for a saw palmetto preparation that the largest independent trial could not distinguish from placebo. You cannot have it both ways, and the combination trials cannot tell you which way it is.

There is one more caveat that applies across this whole literature: most of these trials were funded or conducted by the manufacturers of the products tested, and most were run in Germany and Eastern Europe in the 1990s and 2000s, when phytotherapy was mainstream urological practice there. That does not make them wrong. It does mean independent replication is thinner than the number of published papers suggests.

PSA, Finasteride, and the Thing That Actually Matters

Nearly every article about nettle root includes the line “it does not lower PSA” and moves straight on. That sentence is usually delivered as a limitation, as though a herb that fails to move a lab value has fallen short. It is the opposite. It is arguably the most clinically useful thing about the herb, and it takes a paragraph to explain why.

Prostate-specific antigen is a protein made by prostate tissue and measurable in blood. It is not a cancer test — benign enlargement, infection, recent ejaculation and a rectal examination all raise it — but a PSA level that is high for a man’s age, or that is climbing over time, is the main trigger for further investigation of possible prostate cancer.

The 5-alpha-reductase inhibitors halve it. Finasteride and dutasteride reduce serum PSA by roughly 50% within six to twelve months in essentially every man who takes them. This is a direct pharmacological consequence of shutting down DHT production in prostate tissue. It is well characterised, it is expected, and it is manageable — the standard clinical practice is to double a PSA result measured on one of these drugs before interpreting it. But it must be remembered, by the man and by whoever orders the test. A PSA of 3.0 in a man on finasteride is really a 6.0. If that man moves practice, or sees a locum, or forgets to mention the drug, a result that should have prompted urgent referral reads as unremarkable. The Prostate Cancer Prevention Trial (Thompson 2003) — nearly 19,000 men over seven years — found finasteride reduced overall prostate cancer prevalence but was associated with a higher proportion of high-grade tumours among cancers detected, and the argument over how much of that was a genuine biological effect versus an artefact of the drug altering both PSA and prostate volume ran for years afterwards. That is how much trouble a drug that changes the screening test can cause.

Nettle root does none of this. In Safarinejad’s six-month trial, serum PSA and testosterone were unchanged in both the treated and the placebo group while symptoms and flow rates improved. A man on nettle root has a PSA that means what it says.

So the honest framing is: nettle root relieves symptoms without disturbing the cancer-screening signal, whereas finasteride relieves symptoms and disturbs it in a way that has to be actively corrected for. That is a real advantage, and it is not the advantage most people think they are reading about.

Two things it is not. It is not evidence that nettle prevents or treats prostate cancer — there is no such evidence, and the cell-culture work on prostate cancer lines does not constitute any. And it is not permission to skip screening. An undisturbed PSA is only useful if somebody actually measures it.

Does It Shrink the Prostate?

Mostly no, and the exception is smaller than it looks.

Finasteride genuinely shrinks the gland — on the order of 20–25% of prostate volume over six to twelve months. That is why it, unlike alpha-blockers, reduces the long-term risk of acute urinary retention and the need for surgery. It is treating the anatomy, not just the plumbing symptoms.

Nettle root does not do that to any comparable degree. Safarinejad measured a fall from 40.1 mL to 36.3 mL — about 9%, statistically significant in a 620-man trial but small enough that its clinical meaning is uncertain, and not replicated elsewhere. The prevailing picture from the wider literature is that phytotherapy for BPH eases symptoms without materially reducing gland size.

The practical consequence: nettle root is a symptom treatment. It should not be expected to reduce your risk of ending up in retention or in an operating theatre, because nothing has shown that it does. If your prostate is large, your symptoms are severe, or your urologist has raised the possibility of retention, that is a conversation about a 5-alpha-reductase inhibitor or surgery — not a conversation about a herb.

Dose, Form, Cost and How Long to Give It

Standardized root extract: the dose used in the combination trials is 120 mg twice daily. Single-agent products commonly supply 300–600 mg of root or root-equivalent per day, split into two doses.
Extraction matters. European trial products are typically 20% methanolic or ethanolic extracts. A capsule of plain milled root powder is a different, weaker product than a concentrated extract at the same milligram number — check whether the label says “extract” and gives a ratio (for example 5:1) or a marker compound.
Tincture: a liquid root extract, dosed per the manufacturer’s instructions. Harder to relate to trial doses; there is no standard conversion.
Nettle tea does not count. Tea is made from leaf. It will not treat your prostate.
Timeline: the trials measured at 8, 24 and 48 weeks. Give it at least six to eight weeks at a proper dose before judging it, and note that Safarinejad’s 18-month follow-up showed benefit persisted only in men who kept taking it. There is no evidence of a lasting effect after stopping.
Cost: nettle root is one of the cheaper botanicals — typically a few pounds or dollars a month, well below the branded European combination products. Generic finasteride is also inexpensive, so cost is not a strong argument in either direction.
Keep a symptom diary. Fill in an IPSS questionnaire before you start and again at eight weeks. Herbal effects in this area are modest enough that memory is not a reliable instrument. If the score has not moved 3 points, it is not working for you.

Where Nettle Root Sits Next to Real Drugs

For an honest comparison, here is what conventional treatment offers:

Alpha-blockers (tamsulosin, alfuzosin, doxazosin) relax smooth muscle in the prostate and bladder neck. They work fast — days to a couple of weeks — and typically improve IPSS by 4 to 6 points. Side effects include dizziness, low blood pressure on standing, and retrograde ejaculation. They also complicate cataract surgery (intraoperative floppy iris syndrome), so tell your ophthalmologist.
5-alpha-reductase inhibitors (finasteride, dutasteride) shrink the gland over months, reduce retention and surgery risk, and are most useful in larger prostates. Side effects include reduced libido, erectile difficulty and ejaculatory problems in a minority of men. They halve PSA.
Tadalafil 5 mg daily is licensed for BPH symptoms and has the obvious side benefit for men who also have erectile dysfunction.
Behavioural measures — limiting fluids in the evening, cutting caffeine and alcohol, double voiding, and reviewing any medication with anticholinergic or diuretic effects — are underrated and free. The AUA guideline puts behavioural change and watchful waiting first for mild symptoms, and so should you.

A reasonable place for nettle root: mild to moderate symptoms, in a man who has been properly assessed, who is not keen on drug side effects, and who is prepared to reassess in a couple of months rather than drift indefinitely. An unreasonable place: severe symptoms, blood in the urine, an episode of retention, a rising PSA, or any symptom that has not been evaluated.

Get the Diagnosis First — This Part Is Not Optional

Early prostate cancer and benign enlargement produce the same symptoms. Weak stream, hesitancy, frequency, nocturia — none of these distinguishes between them. Neither does a symptom questionnaire. Neither does how you feel.

What distinguishes them is assessment: history and examination, a urine test to rule out infection, a PSA measurement interpreted for your age, a digital rectal examination, and depending on findings, imaging or referral. A man who treats his symptoms with a herb, feels somewhat better, and therefore never gets assessed has bought himself an unknown amount of delay. Symptom relief is not reassurance.

Go now, not later, if you have any of: blood in the urine or semen; inability to pass urine at all (this is an emergency); fever with urinary symptoms; new bone pain, particularly in the back, hips or ribs; unexplained weight loss; a rapid change in symptoms over weeks; or a family history of prostate cancer, especially in a father or brother diagnosed young.

Cautions and Interactions

Nettle root is one of the better-tolerated botanicals. Safarinejad’s 620-man trial identified no side effects in either arm, and the combination-product trials consistently report fewer adverse events than the comparator drugs. That said:

Gastrointestinal upset — mild nausea, loose stools or cramping, usually dose-related and usually settling. The most commonly reported complaint.
Blood pressure and diuretics. An aqueous extract of nettle’s aerial parts produced dose-dependent falls in blood pressure with increased urine and sodium output when infused intravenously into rats (Tahri 2000) — an animal study at doses that are not comparable to a capsule, but a reason to watch for lightheadedness if you take antihypertensives or diuretics alongside nettle. The higher dose in that study appeared to be toxic, which is worth knowing about the general enthusiasm for “more is better”.
Diabetes medication. Nettle leaf has shown modest glucose-lowering effects in small trials. If you take a whole-plant product alongside insulin or a sulfonylurea, monitor for hypoglycaemia.
Warfarin. This is a leaf issue, not a root issue — root extract is not a meaningful vitamin K source — but if your product is a whole-plant blend, see the nutrition article, because the vitamin K content of nettle leaf is a genuine anticoagulation problem.
Lithium. Any agent with a diuretic effect can theoretically alter lithium levels. Coordinate with whoever monitors them.
Pregnancy and breastfeeding. Not applicable to this indication, but for completeness: medicinal doses of nettle are traditionally avoided in pregnancy and safety data are inadequate.
Tell your doctor. Not as a ritual disclaimer — because a supplement that eases symptoms can mask a change worth investigating, and because whoever interprets your next PSA should know everything you are taking.

Key Research Papers

Every identifier below was verified live against NCBI E-utilities before being written. Study type is labelled — human, animal or cell culture — because the difference matters more here than anywhere else on this page.

Safarinejad MR. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. Journal of Herbal Pharmacotherapy. 2005;5(4):1–11. Human RCT, n = 620. The largest single-agent trial; IPSS 19.8 → 11.8; PSA unchanged.
Ghorbanibirgani A, Khalili A, Zamani L. The efficacy of stinging nettle (Urtica dioica) in patients with benign prostatic hyperplasia: a randomized double-blind study in 100 patients. Iranian Red Crescent Medical Journal. 2013;15(1):9–10. Human RCT, n = 100. Brief report; positive but thinly described.
Lopatkin N, Sivkov A, Walther C, et al. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms — a placebo-controlled, double-blind, multicenter trial. World Journal of Urology. 2005;23(2):139–146. Human RCT, combination product.
Lopatkin N, Sivkov A, Schläfke S, et al. Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms — long-term follow-up of a placebo-controlled, double-blind, multicenter trial. International Urology and Nephrology. 2007;39(4):1137–1146. Human, open extension.
Sökeland J. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. BJU International. 2000;86(4):439–442. Human, subgroup analysis of 431 of 543 randomized men. Q_max +1.9 vs +2.4 mL/s, P = 0.52; fewer adverse events on the herbal arm.
Engelmann U, Walther C, Bondarenko B, Funk P, Schläfke S. Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms: a randomized, double-blind study versus tamsulosin. Arzneimittelforschung. 2006;56(3):222–229. Human RCT versus active comparator.
Krzeski T, Kazón M, Borkowski A, Witeska A, Kuczera J. Combined extracts of Urtica dioica and Pygeum africanum in the treatment of benign prostatic hyperplasia: double-blind comparison of two doses. Clinical Therapeutics. 1993;15(6):1011–1020. Human, n = 134, dose comparison — no placebo arm.
Vontobel HP, Herzog R, Rutishauser G, Kres H. [Results of a double-blind study on the effectiveness of ERU (extractum radicis Urticae) capsules in conservative treatment of benign prostatic hyperplasia]. Der Urologe A. 1985;24(1):49–51. Human, early German trial; German-language.
Schöttner M, Gansser D, Spiteller G. Lignans from the roots of Urtica dioica and their metabolites bind to human sex hormone binding globulin (SHBG). Planta Medica. 1997;63(6):529–532. Cell-free binding assay.
Lichius JJ, Muth C. The inhibiting effects of Urtica dioica root extracts on experimentally induced prostatic hyperplasia in the mouse. Planta Medica. 1997;63(4):307–310. Animal.
Nahata A, Dixit VK. Ameliorative effects of stinging nettle (Urtica dioica) on testosterone-induced prostatic hyperplasia in rats. Andrologia. 2012;44 Suppl 1:396–409. Animal.
Konrad L, Müller HH, Lenz C, et al. Antiproliferative effect on human prostate cancer cells by a stinging nettle root (Urtica dioica) extract. Planta Medica. 2000;66(1):44–47. Cell culture. Not evidence of an effect on prostate cancer in people.
Chrubasik JE, Roufogalis BD, Wagner H, Chrubasik S. A comprehensive review on the stinging nettle effect and efficacy profiles. Part II: urticae radix. Phytomedicine. 2007;14(7–8):568–579. Review. The standard reference for the root.
Barry MJ, Meleth S, Lee JY, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA. 2011;306(12):1344–1351. Human RCT, n = 369, negative. Context for the combination products.
Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. New England Journal of Medicine. 2003;349(3):215–224. Human RCT. Why a drug that changes PSA causes arguments.
Sandhu JS, Bixler BR, Dahm P, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. The Journal of Urology. 2024;211(1):11–19. Guideline.
Tahri A, Yamani S, Legssyer A, et al. Acute diuretic, natriuretic and hypotensive effects of a continuous perfusion of aqueous extract of Urtica dioica in the rat. Journal of Ethnopharmacology. 2000;73(1–2):95–100. Animal. Basis of the blood-pressure caution.

Live PubMed Searches

Connections

All Herbs
Stinging Nettle — main article
Stinging Nettle Benefits — hub
Leaf for Allergies and Hay Fever
Nutrition, Iron and Nettle as Food
Joint Pain and Traditional Urtication
Saw Palmetto — the other half of most combination products
Benign Prostatic Hyperplasia
Urology

Back to Table of Contents